Centanafadine Schedule III interim rule
Published November 4, 2026 · Coverage October 25–31, 2026, Pacific · Medium priority
DEA issued an interim final rule placing centanafadine, including its salts, isomers and salts of isomers where possible, in Schedule III effective October 30, 2026. The rule requests comments by November 30. The rule's actual provisions and applicability should be reviewed for an organization's circumstances; this summary does not assert a particular patient's treatment or a universal prescribing change.
Why it matters: Pharmacy, procurement and controlled-substance compliance teams at organizations handling or expecting to handle centanafadine may need to assess the scheduling against their own operations. It does not establish a universal change to every prescribing workflow.
Suggested action: Responsible teams can determine whether they handle the substance, review the rule and applicable requirements, and assess whether internal procedures or staff information need updating.
Complete edition and supplemental material
This article in the complete report →
Executive triage, source-coverage limitations, context and forward horizons remain in the complete report.
Read the entire Compliance Sweep report →